Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...